X4 Pharmaceuticals, Inc

(NASDAQ:XFOR)

Latest On X4 Pharmaceuticals, Inc (XFOR):

Date/Time Type Description Signal Details
2023-05-16 20:33 ESTNewsX4 Pharmaceuticals scales 12% on $65M private placementN/A
2023-05-06 21:22 ESTNewsX4 Pharmaceuticals, Inc. (XFOR) Q1 2023 Earnings Call TranscriptN/A
2023-05-04 18:27 ESTNewsX4 Pharmaceuticals GAAP EPS of -$0.16 beats by $0.05N/A
2023-04-12 23:41 ESTNewsX4 Pharma jumps 22% on upcoming data readout for lead assetN/A
2023-04-12 09:36 ESTNewsX4 Pharmaceuticals: Chronic Neutropenia Might Finally Have Met Its MatchN/A
2023-03-22 03:23 ESTNewsX4 Pharmaceuticals, Inc. (XFOR) Q4 2022 Earnings Call TranscriptN/A
2023-03-21 12:00 ESTNewsX4 Pharmaceuticals GAAP EPS of -$0.29 misses by $0.05N/A
2023-01-25 09:41 ESTNewsX4 Pharmaceuticals: A Worthy $1 'Dart Throw'N/A
2022-12-07 23:01 ESTNewsX4 Pharmaceuticals stock dips after pricing $65M securities offeringN/A
2022-12-07 03:20 ESTNewsX4 Pharmaceuticals stock sheds 14% on proposed securities offeringN/A
2022-11-30 08:22 ESTNewsX4 Pharma sheds 16% even as rare disease therapy meets main goal in Phase 3 trialN/A
2022-11-05 20:40 ESTNewsX4 Pharmaceuticals, Inc. (XFOR) Q3 2022 Earnings Call TranscriptN/A
2022-11-03 17:51 ESTNewsX4 Pharmaceuticals GAAP EPS of -$0.26 beats by $0.04N/A
2022-09-27 19:02 ESTNewsX4 stock rises 10% as mavorixafor shows promise in trial for white blood cell disorderN/A
2022-09-19 14:01 ESTNewsX4 Pharmaceuticals: Upcoming CatalystsN/A
2022-08-07 13:38 ESTNewsX4 Pharmaceuticals, Inc. 2022 Q2 - Results - Earnings Call PresentationN/A
2022-08-07 13:37 ESTNewsX4 Pharmaceuticals, Inc.'s (XFOR) CEO Dr. Paula Ragan on Q2 2022 Results - Earnings Call TranscriptN/A
2022-08-04 18:59 ESTNewsX4 Pharmaceuticals GAAP EPS of -$0.60 beats by $0.04N/A
2022-07-21 04:22 ESTNewsX4 Pharma to focus resources on lead drug candidate, cut workforce by about 20%N/A
2022-07-01 13:30 ESTNewsX4 Pharmaceuticals to raise $55M in stock and warrants offering, debt facility amendedN/A
2022-05-13 02:49 ESTNewsX4 Pharmaceuticals, Inc. (XFOR) CEO Paula Ragan on Q1 2022 Results - Earnings Call TranscriptN/A
2022-05-12 06:46 ESTNewsX4 Pharmaceuticals GAAP EPS of -$0.72 misses by $0.11N/A
2022-03-18 03:06 ESTNewsX4 Pharmaceuticals GAAP EPS of -$1.24 misses by $0.56N/A
2022-03-18 03:06 ESTNewsX4 Pharmaceuticals, Inc. 2021 Q4 - Results - Earnings Call PresentationN/A
2022-03-18 03:05 ESTNewsX4 Pharmaceuticals, Inc. (XFOR) CEO Paula Ragan on Q4 2021 Results - Earnings Call TranscriptN/A
2021-12-15 00:31 ESTNewsX4 Pharma defended at H.C. Wainwright ahead of more data on blood cell cancer therapyN/A
2021-12-13 09:59 ESTNewsX4 down 24% on mavorixafor data in mid-stage study for immunodeficiency disorderN/A
2021-11-12 11:18 ESTNewsWarning: XFOR is at high risk of performing badlyN/A
2021-11-06 11:04 ESTNewsX4 Pharmaceuticals, Inc. (XFOR) CEO Paula Ragan on Q3 2021 Results - Earnings Call TranscriptN/A
2021-09-08 18:36 ESTNewsX4 Pharmaceuticals promotes Mary Dibiase to Chief Operating OfficerN/A
2021-08-07 09:22 ESTNewsX4 Pharmaceuticals, Inc. (XFOR) CEO Paula Ragan on Q2 2021 Results - Earnings Call TranscriptN/A
2021-08-03 21:24 ESTNewsX4 Pharmaceuticals EPS in-lineN/A
2021-08-03 21:22 ESTNewsX4 Pharma: Late Stage Nanocap Targeting Rare DiseasesN/A
2021-07-22 09:24 ESTNewsX4 Pharmaceuticals reports early-stage data for ibrutinib in lymphomaN/A
2021-05-06 21:58 ESTNewsX4 Pharmaceuticals EPS misses by $0.44N/A
2021-03-20 05:38 ESTNewsX4 Pharmaceuticals enters $55M capital raiseN/A
2021-03-16 22:27 ESTAnalyst RatingThe Analyst Target Price has increased from $18.63 to $19.29.Buy
2021-03-06 20:54 ESTFinancialsCompany financials have been released.Neutral
2021-03-05 12:40 ESTEarnings EstimateAn EPS average of -$0.88 is estimated for the quarter ending on June 30, 2021.Buy
2021-03-05 12:40 ESTEarnings EstimateAn EPS average of -$3.38 is estimated for the 2022 year.Sell
2021-03-05 12:40 ESTAnalyst RatingThe Analyst Target Price has decreased from $18.75 to $18.63.Neutral
2021-03-05 08:29 ESTNewsX4 Pharmaceuticals, Inc. (XFOR) CEO Paula Ragan on Q4 2020 Results - Earnings Call TranscriptN/A
2021-03-04 11:43 ESTNewsX4 Pharmaceuticals EPS misses by $0.03N/A
2020-12-18 13:32 ESTAnalyst RatingThe Analyst Target Price has increased from $18.43 to $18.75.Buy
2020-12-10 20:46 ESTNewsX4 Pharma's lead program nabs Rare Pediatric tag for inherited immunodeficiency disorderN/A
2020-11-26 22:09 ESTFinancialsCompany financials have been released.Neutral
2020-11-10 13:32 ESTAnalyst RatingThe Analyst Target Price has decreased from $18.71 to $18.43.Neutral
2020-11-08 01:21 ESTFinancialsCompany financials have been released.Neutral
2020-11-07 19:51 ESTNewsX4 Pharmaceuticals, Inc. (XFOR) CEO Paula Ragan on Q3 2020 Results - Earnings Call TranscriptN/A
2020-11-07 17:37 ESTFinancialsCompany financials have been released.Neutral

About X4 Pharmaceuticals, Inc (XFOR):

X4 Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for the treatment of primary immune-deficiencies and cancer. Its lead drug candidate is mavorixafor (X4P-001), an oral small molecule antagonist of chemokine receptor CXCR4, which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; Phase Ib clinical trial to treat severe congenital neutropenia and Waldenström macroglobulinemia; and Phase IIa clinical trial for the treatment of clear cell renal cell carcinoma. The company is also developing X4P-002 for the treatment of glioblastoma multiforme; and X4P-003 to treat primary immune-deficiencies. It has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company was formerly known as Arsanis, Inc. and changed its name to X4 Pharmaceuticals, Inc. in March 2019. X4 Pharmaceuticals, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.

XFOR Quotes by TradingView

See Advanced Chart

General

  • Name X4 Pharmaceuticals, Inc
  • Symbol XFOR
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Last Split Factor1:6
  • Last Split Date2019-03-14
  • Fiscal Year EndDecember
  • IPO Date2017-11-16
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Web URLhttp://www.x4pharma.com
View More

Valuation

  • Trailing PE 5.49
  • Price/Sales (Trailing 12 Mt.) 60.66
  • Price/Book (Most Recent Quarter) 1.72
  • Enterprise Value Revenue 32.29
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$3.42
  • Next Year EPS Estimate -$3.04
  • Next Quarter EPS Estimate -$0.88
  • Operating Margin -1996%
  • Return on Assets -26%
  • Return on Equity -62%
  • Revenue 3 million
  • Earnings Per Share -$3.72
  • Revenue Per Share $0.15
  • Gross Profit 3 million
  • Quarterly Earnings Growth 0%
View More

Highlights

  • Market Capitalization 144.95 million
  • EBITDA -40355000
  • Analyst Target Price $19.29
  • Book Value Per Share $3.61
View More

Share Statistics

  • Shares Outstanding 16.29 million
  • Shares Float 15.45 million
  • % Held by Insiders 237%
  • % Held by Institutions 66.29%
  • Shares Short 469188
  • Shares Short Prior Month 427195
  • Short Ratio 4.01
  • Short % of Float 3%
  • Short % of Shares Outstanding 3%
View More

Technicals

  • Beta 0.25
  • 52 Week High $11.11
  • 52 Week Low $5.38
  • 50 Day Moving Average 9.04
  • 200 Day Moving Average 7.48
View More

Dividends

  • Dividend Date 2019-03-14
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

X4 Pharmaceuticals, Inc (XFOR) Dividend Calendar:

XFOR's last dividend payment was made to shareholders on March 14, 2019.

Ex-Dividend Date Payment Date Record Date Declared Date Amount

X4 Pharmaceuticals, Inc (XFOR) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-03-04$N/A-$0.91-$0.90-1.31%
2020-09-302020-11-05$N/A-$0.87-$0.73-18.77%
2020-06-302020-07-30$N/A-$0.76-$0.71-7.1%
2020-03-312020-05-07$N/A-$0.56-$0.8332.77%
2019-12-312020-03-12$N/A-$0.66-$0.7714.1%
2019-09-302019-11-07$N/A-$1.22-$1.01-20.41%
2019-06-302019-08-07$N/A-$1.02-$0.85-19.48%
2019-03-312019-05-15$N/A-$6.67-$3.30-102.18%
2018-12-312019-03-11$N/A-$3.92-$4.4411.71%
2018-09-302018-11-09-$4.56-$3.88-17.53%
2018-06-302018-08-13$N/A-$5.10-$4.90-4.08%
2018-03-312018-05-10$N/A-$4.44-$6.2428.85%
2017-12-312018-03-09$N/A-$10.08-$17.8043.37%
2017-09-302017-11-17-$29.25

X4 Pharmaceuticals, Inc (XFOR) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date Dec 31 2020 Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019
Research Development N/A N/A N/A N/A 7.07 million
Income Before Tax N/A N/A N/A N/A -10.84 million
Selling General Administrative N/A N/A N/A N/A 3.91 million
Gross Profit N/A N/A N/A N/A N/A
Ebit N/A N/A N/A N/A -10.98 million
Operating Income N/A N/A N/A N/A -10.98 million
Income Tax Expense N/A N/A N/A 148000 N/A
Total Revenue N/A N/A N/A N/A N/A
Cost of Revenue N/A N/A N/A N/A N/A
Total Other Income Expense Net N/A N/A N/A N/A 142000
Net Income From Continuing Operations N/A N/A N/A N/A -10.84 million
Net Income Applicable to Common Shares -18.4 million -17.45 million -15.14 million -11.14 million -10.84 million
Cash Flow:
Date Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019 Sep 30 2019
Investments N/A N/A N/A N/A N/A
Change to Liabilities 211000 800000 -800000 N/A N/A
Total Cash Flow from Investing Activities -496000 -9000 -555000 21000 815000
Net Borrowings -4.89 million -4.89 million 4.89 million N/A N/A
Total Cash Flow from Financial Activities N/A N/A N/A 60.28 million -6.41 million
Change to Operating Activities 303000 -1.55 million -1.75 million 740000 -733000
Change in Cash N/A N/A N/A 51.08 million -18.64 million
Total Cash from Operating Activities -14.33 million -11.46 million -15.53 million -9.24 million -12.77 million
Depreciation N/A N/A N/A N/A N/A
Other Cash Flow from Investing Activities -1.06 million -564000 N/A 21000 815000
Change to Inventory N/A N/A N/A N/A N/A
Change to Account Receivables N/A N/A N/A N/A N/A
Other Cash Flow from Financing Activities 4.77 million 5.05 million N/A 60.28 million -6.41 million
Change to Net Income 2.96 million 1.59 million 1 million 856000 5.68 million
Capital Expenditures N/A N/A N/A N/A N/A
Balance Sheet:
Date Dec 31 2020 Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019
Total Liabailities N/A N/A N/A N/A 31.48 million
Total Stockholder Equity N/A N/A N/A N/A 129.22 million
Other Current Liabilities N/A N/A N/A N/A N/A
Total Assets N/A N/A N/A N/A 160.7 million
Common Stock 72.8 million 89.71 million 104.88 million 16000 129.22 million
Other Current Assets N/A N/A N/A N/A N/A
Retained Earnings N/A N/A N/A -143.18 million N/A
Other Liabilities 462000 25000 26000 26000 16000
Other Assets 3.26 million 2.55 million 3.47 million 2.38 million 1.95 million
Cash N/A N/A N/A N/A 126.18 million
Total Current Liabilities 11.95 million 13.18 million N/A N/A 9.45 million
Other Stockholder Equity N/A N/A N/A -119000 N/A
Property, Plant & Equipment 9.2 million 9.56 million 2.07 million 2.28 million 2.36 million
Total Current Assets 83.31 million 93.91 million N/A N/A 129.28 million
Long Term Investments N/A N/A N/A N/A N/A
Net Tangible Assets 45.69 million 62.6 million 77.78 million 91.68 million 102.11 million
Short Term Investments N/A N/A N/A N/A N/A
Long Term Debt N/A N/A N/A N/A 20.1 million
Inventory N/A N/A N/A N/A N/A
Accounts Payable 3.14 million 3.89 million N/A N/A 2.09 million

X4 Pharmaceuticals, Inc (XFOR) Chart:

X4 Pharmaceuticals, Inc (XFOR) News:

Below you will find a list of latest news for X4 Pharmaceuticals, Inc (XFOR) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

X4 Pharmaceuticals, Inc (XFOR) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2025-01-170.50.23CALL0 539119.38TRUE00
2025-01-1710.05CALL0 1928138.95FALSE00
2025-01-171.50.05CALL0 7430FALSE00
2025-01-1720.05CALL0 6890FALSE00
2025-01-172.50.05CALL0 1680FALSE00
2025-01-1730.08CALL0 5250FALSE00
2025-01-1740CALL0 00FALSE00
2025-01-170.50.1PUT0 1450FALSE00
2025-01-1710.42PUT4 1176112.95TRUE0.420
2025-01-171.50.8PUT0 1130TRUE00
2025-01-1721.35PUT0 00TRUE00
2025-01-172.51.4PUT0 00TRUE00
2025-01-1730PUT0 0209.67TRUE00
2025-01-1740PUT0 0283.48TRUE00
2025-02-210.50CALL0 00TRUE00
2025-02-2110.1CALL0 70FALSE00
2025-02-211.50CALL0 00FALSE00
2025-02-2120.05CALL0 210FALSE00
2025-02-2130CALL0 00FALSE00
2025-02-2140CALL0 00FALSE00
2025-02-210.50PUT0 00FALSE00
2025-02-2110.35PUT0 150TRUE00
2025-02-211.50PUT0 00TRUE00
2025-02-2120PUT0 00TRUE00
2025-02-2130PUT0 00TRUE00
2025-02-2140PUT0 0507.28TRUE00
2025-05-1610CALL0 00FALSE00
2025-05-1620CALL0 00FALSE00
2025-05-1630CALL0 00FALSE00
2025-05-1640CALL0 00FALSE00
2025-05-1610PUT0 00TRUE00
2025-05-1620PUT0 00TRUE00
2025-05-1630PUT0 00TRUE00
2025-05-1640PUT0 0207.78TRUE00
2026-01-160.50.4CALL5 47138.42TRUE00
2026-01-1610.3CALL0 2431108.17FALSE00
2026-01-161.50.2CALL0 79112.7FALSE00
2026-01-1621.1CALL0 660FALSE00
2026-01-162.50.1CALL0 40FALSE00
2026-01-1630.13CALL0 10350FALSE00
2026-01-160.50.25PUT0 980FALSE00
2026-01-1610.5PUT0 145107.5TRUE00
2026-01-161.50PUT0 00TRUE00
2026-01-1620PUT0 00TRUE00
2026-01-162.50PUT0 00TRUE00
2026-01-1630PUT0 00TRUE00

Latest XFOR Trades:

Date Shares Price
Jun 13, 2022 7:33 PM EST8$1.185
Jun 13, 2022 7:42 PM EST100$1.185
Jun 13, 2022 7:55 PM EST7$1.19
Jun 13, 2022 7:57 PM EST6$1.19
Jun 13, 2022 7:57 PM EST87$1.19

X4 Pharmaceuticals, Inc (XFOR) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-07-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1501697/000162828020010103/0001628280-20-010103-index.htm
2019-08-14UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1501697/000000000019012485/0000000000-19-012485-index.htm
2020-08-12UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1501697/000000000020007394/0000000000-20-007394-index.htm
2019-05-10SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1501697/000031506619001526/0000315066-19-001526-index.htm
2020-09-10SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1501697/000031506620001733/0000315066-20-001733-index.htm
2019-03-15SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1501697/000089843219000393/0000898432-19-000393-index.htm
2019-03-143Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1501697/000089924319007797/0000899243-19-007797-index.htm
2019-03-143Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1501697/000089924319007801/0000899243-19-007801-index.htm
2019-03-143Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1501697/000089924319007803/0000899243-19-007803-index.htm
2019-03-143Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1501697/000089924319007806/0000899243-19-007806-index.htm
2019-03-143Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1501697/000089924319007811/0000899243-19-007811-index.htm
2019-03-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1501697/000089924319007818/0000899243-19-007818-index.htm
2019-03-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1501697/000089924319007821/0000899243-19-007821-index.htm
2019-03-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1501697/000089924319007824/0000899243-19-007824-index.htm
2019-03-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1501697/000089924319007828/0000899243-19-007828-index.htm
2019-03-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1501697/000089924319007832/0000899243-19-007832-index.htm
2019-03-154/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1501697/000089924319007975/0000899243-19-007975-index.htm
2019-04-023Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1501697/000089924319009662/0000899243-19-009662-index.htm
2019-04-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1501697/000089924319009663/0000899243-19-009663-index.htm
2019-04-024/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1501697/000089924319009669/0000899243-19-009669-index.htm
2019-04-024/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1501697/000089924319009670/0000899243-19-009670-index.htm
2019-04-024/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1501697/000089924319009671/0000899243-19-009671-index.htm
2019-04-263Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1501697/000089924319011288/0000899243-19-011288-index.htm
2019-04-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1501697/000089924319011289/0000899243-19-011289-index.htm
2019-06-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1501697/000089924319017419/0000899243-19-017419-index.htm
2019-06-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1501697/000089924319017421/0000899243-19-017421-index.htm
2019-06-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1501697/000089924319017422/0000899243-19-017422-index.htm
2019-06-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1501697/000089924319017423/0000899243-19-017423-index.htm
2019-04-23SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1501697/000092189519001144/0000921895-19-001144-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1501697/000092189520000573/0000921895-20-000573-index.htm
2019-04-22SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1501697/000092963819000464/0000929638-19-000464-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1501697/000092963820000335/0000929638-20-000335-index.htm
2019-12-17SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1501697/000093583619000662/0000935836-19-000662-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1501697/000093583620000152/0000935836-20-000152-index.htm
2019-03-19SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1501697/000094787119000210/0000947871-19-000210-index.htm
2019-04-19SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1501697/000094787119000298/0000947871-19-000298-index.htm
2019-05-28SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1501697/000107261319000202/0001072613-19-000202-index.htm
2020-02-14SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1501697/000110465920021897/0001104659-20-021897-index.htm
2019-02-14424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1501697/000119312519041008/0001193125-19-041008-index.htm
2019-03-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1501697/000119312519061101/0001193125-19-061101-index.htm
2019-03-01425Prospectuses and communications, business combinationshttps://www.sec.gov/Archives/edgar/data/1501697/000119312519061104/0001193125-19-061104-index.htm
2019-03-01DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1501697/000119312519061118/0001193125-19-061118-index.htm
2019-03-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1501697/000119312519069279/0001193125-19-069279-index.htm
2019-03-08425Prospectuses and communications, business combinationshttps://www.sec.gov/Archives/edgar/data/1501697/000119312519069282/0001193125-19-069282-index.htm
2019-03-08DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1501697/000119312519069299/0001193125-19-069299-index.htm
2019-03-11S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1501697/000119312519070143/0001193125-19-070143-index.htm
2019-03-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1501697/000119312519073465/0001193125-19-073465-index.htm
2019-03-22SC 13DGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1501697/000119312519083526/0001193125-19-083526-index.htm
2019-03-25S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1501697/000119312519085450/0001193125-19-085450-index.htm
2019-04-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1501697/000119312519093803/0001193125-19-093803-index.htm
2019-04-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1501697/000119312519095201/0001193125-19-095201-index.htm
2019-04-038-K/ACurrent reporthttps://www.sec.gov/Archives/edgar/data/1501697/000119312519095792/0001193125-19-095792-index.htm
2019-04-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1501697/000119312519103832/0001193125-19-103832-index.htm
2019-04-12424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1501697/000119312519104409/0001193125-19-104409-index.htm
2019-04-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1501697/000119312519104421/0001193125-19-104421-index.htm
2019-04-12FWPFiling under Securities Act Rules 163/433 of free writing prospectuseshttps://www.sec.gov/Archives/edgar/data/1501697/000119312519104620/0001193125-19-104620-index.htm
2019-04-15424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1501697/000119312519106612/0001193125-19-106612-index.htm
2019-04-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1501697/000119312519106621/0001193125-19-106621-index.htm
2019-04-26SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1501697/000119312519122305/0001193125-19-122305-index.htm
2019-05-138-K/ACurrent reporthttps://www.sec.gov/Archives/edgar/data/1501697/000119312519145463/0001193125-19-145463-index.htm
2019-05-1510-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1501697/000119312519148119/0001193125-19-148119-index.htm
2019-05-178-K/ACurrent reporthttps://www.sec.gov/Archives/edgar/data/1501697/000119312519150552/0001193125-19-150552-index.htm
2019-05-22DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1501697/000119312519154033/0001193125-19-154033-index.htm
2019-06-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1501697/000119312519176532/0001193125-19-176532-index.htm
2019-06-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1501697/000119312519181950/0001193125-19-181950-index.htm
2019-06-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1501697/000119312519185089/0001193125-19-185089-index.htm
2019-07-17SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1501697/000119312519195714/0001193125-19-195714-index.htm
2019-08-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1501697/000119312519217363/0001193125-19-217363-index.htm
2019-08-09S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1501697/000119312519217393/0001193125-19-217393-index.htm
2019-08-09S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1501697/000119312519217396/0001193125-19-217396-index.htm
2019-08-22CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1501697/000119312519226897/0001193125-19-226897-index.htm
2019-08-22S-3/ARegistration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1501697/000119312519226901/0001193125-19-226901-index.htm
2019-08-27CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1501697/000119312519230219/0001193125-19-230219-index.htm
2019-09-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1501697/000119312519250706/0001193125-19-250706-index.htm
2019-09-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1501697/000119312519258069/0001193125-19-258069-index.htm
2019-10-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1501697/000119312519262851/0001193125-19-262851-index.htm
2019-10-188-K/ACurrent reporthttps://www.sec.gov/Archives/edgar/data/1501697/000119312519270084/0001193125-19-270084-index.htm
2019-11-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1501697/000119312519286603/0001193125-19-286603-index.htm
2019-11-25424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1501697/000119312519299872/0001193125-19-299872-index.htm
2019-11-26FWPFiling under Securities Act Rules 163/433 of free writing prospectuseshttps://www.sec.gov/Archives/edgar/data/1501697/000119312519300492/0001193125-19-300492-index.htm
2019-11-27424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1501697/000119312519302710/0001193125-19-302710-index.htm
2019-11-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1501697/000119312519302716/0001193125-19-302716-index.htm
2019-12-09SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1501697/000119312519309318/0001193125-19-309318-index.htm
2020-03-13S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1501697/000119312520072921/0001193125-20-072921-index.htm
2020-04-17PRE 14AOther preliminary proxy statementshttps://www.sec.gov/Archives/edgar/data/1501697/000119312520110795/0001193125-20-110795-index.htm
2020-04-28DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1501697/000119312520123073/0001193125-20-123073-index.htm
2020-04-28DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1501697/000119312520123083/0001193125-20-123083-index.htm
2020-05-12DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1501697/000119312520140464/0001193125-20-140464-index.htm
2020-08-07S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1501697/000119312520213051/0001193125-20-213051-index.htm
2020-08-17CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1501697/000119312520222413/0001193125-20-222413-index.htm
2020-10-16424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1501697/000119312520271098/0001193125-20-271098-index.htm
2020-10-168-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1501697/000119312520271109/0001193125-20-271109-index.htm
2020-10-19S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1501697/000119312520272057/0001193125-20-272057-index.htm
2019-04-16SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1501697/000119380519000363/0001193805-19-000363-index.htm
2019-12-03SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1501697/000119380519001896/0001193805-19-001896-index.htm
2020-02-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1501697/000119380520000203/0001193805-20-000203-index.htm
2019-09-203Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1501697/000120919119050346/0001209191-19-050346-index.htm
2019-09-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1501697/000120919119050347/0001209191-19-050347-index.htm
2019-11-063Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1501697/000120919119055533/0001209191-19-055533-index.htm
2019-03-1110-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1501697/000156459019007097/0001564590-19-007097-index.htm
2019-08-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1501697/000156459019029551/0001564590-19-029551-index.htm
2019-11-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1501697/000162828019013715/0001628280-19-013715-index.htm
2019-11-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1501697/000162828019014211/0001628280-19-014211-index.htm
2019-11-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1501697/000162828019014580/0001628280-19-014580-index.htm
2020-01-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1501697/000162828020000255/0001628280-20-000255-index.htm
2020-02-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1501697/000162828020001524/0001628280-20-001524-index.htm
2020-03-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1501697/000162828020002798/0001628280-20-002798-index.htm
2020-03-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1501697/000162828020003426/0001628280-20-003426-index.htm
2020-03-1210-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1501697/000162828020003484/0001628280-20-003484-index.htm
2020-03-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1501697/000162828020003723/0001628280-20-003723-index.htm
2020-03-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1501697/000162828020003875/0001628280-20-003875-index.htm
2020-04-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1501697/000162828020004587/0001628280-20-004587-index.htm
2020-05-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1501697/000162828020006483/0001628280-20-006483-index.htm
2020-05-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1501697/000162828020006780/0001628280-20-006780-index.htm
2020-05-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1501697/000162828020006998/0001628280-20-006998-index.htm
2020-06-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1501697/000162828020008920/0001628280-20-008920-index.htm
2020-06-10S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1501697/000162828020009216/0001628280-20-009216-index.htm
2020-06-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1501697/000162828020009230/0001628280-20-009230-index.htm
2020-06-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1501697/000162828020009232/0001628280-20-009232-index.htm
2020-06-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1501697/000162828020009234/0001628280-20-009234-index.htm
2020-06-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1501697/000162828020009236/0001628280-20-009236-index.htm
2020-06-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1501697/000162828020009238/0001628280-20-009238-index.htm
2020-06-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1501697/000162828020009240/0001628280-20-009240-index.htm
2020-06-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1501697/000162828020009266/0001628280-20-009266-index.htm
2020-06-113Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1501697/000162828020009291/0001628280-20-009291-index.htm
2020-06-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1501697/000162828020009293/0001628280-20-009293-index.htm
2020-07-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1501697/000162828020010103/0001628280-20-010103-index.htm
2020-07-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1501697/000162828020010212/0001628280-20-010212-index.htm
2020-07-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1501697/000162828020010927/0001628280-20-010927-index.htm
2020-08-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1501697/000162828020011642/0001628280-20-011642-index.htm
2020-08-0410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1501697/000162828020011644/0001628280-20-011644-index.htm
2020-08-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1501697/000162828020012840/0001628280-20-012840-index.htm
2020-08-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1501697/000162828020012842/0001628280-20-012842-index.htm
2020-08-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1501697/000162828020012844/0001628280-20-012844-index.htm
2020-08-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1501697/000162828020012846/0001628280-20-012846-index.htm
2020-09-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1501697/000162828020013295/0001628280-20-013295-index.htm
2020-09-104Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1501697/000162828020013419/0001628280-20-013419-index.htm
2020-09-104Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1501697/000162828020013422/0001628280-20-013422-index.htm
2020-09-104Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1501697/000162828020013423/0001628280-20-013423-index.htm
2020-09-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1501697/000162828020013500/0001628280-20-013500-index.htm
2020-09-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1501697/000162828020013832/0001628280-20-013832-index.htm
2020-10-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1501697/000162828020014094/0001628280-20-014094-index.htm
2020-10-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1501697/000162828020014296/0001628280-20-014296-index.htm
2020-10-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1501697/000162828020014320/0001628280-20-014320-index.htm
2020-10-063Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1501697/000162828020014322/0001628280-20-014322-index.htm
2020-10-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1501697/000162828020014324/0001628280-20-014324-index.htm
2020-10-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1501697/000162828020014331/0001628280-20-014331-index.htm
2020-10-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1501697/000162828020014372/0001628280-20-014372-index.htm
2020-10-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1501697/000162828020014661/0001628280-20-014661-index.htm
2020-11-033Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1501697/000162828020015312/0001628280-20-015312-index.htm
2020-11-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1501697/000162828020015597/0001628280-20-015597-index.htm
2020-11-0510-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1501697/000162828020015792/0001628280-20-015792-index.htm
2019-02-14EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1501697/999999999519000261/9999999995-19-000261-index.htm
2019-02-19EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1501697/999999999519000298/9999999995-19-000298-index.htm
2019-08-29EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1501697/999999999519002010/9999999995-19-002010-index.htm
2020-08-19EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1501697/999999999520002202/9999999995-20-002202-index.htm
2020-10-26EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1501697/999999999520002979/9999999995-20-002979-index.htm

X4 Pharmaceuticals, Inc (XFOR) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of X4 Pharmaceuticals, Inc (XFOR). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 237%
Institutional Ownership: 6629%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2019-06-17Adam S. MostafaCFO and TreasurerBuy10,564.0010,564.00https://www.sec.gov/Archives/edgar/data/1501697/000089924319017421/0000899243-19-017421-index.htm
2020-08-14Derek M MeisnerGeneral CounselBuy12,500.0012,500.00https://www.sec.gov/Archives/edgar/data/1501697/000162828020012840/0001628280-20-012840-index.htm
2020-09-09Derek M MeisnerGeneral CounselSell8,334.008.0567,088.7016,666.00https://www.sec.gov/Archives/edgar/data/1501697/000162828020013419/0001628280-20-013419-index.htm
2019-03-13Paula RaganPresident and CEOBuy181,366.00181,366.00https://www.sec.gov/Archives/edgar/data/1501697/000089924319007818/0000899243-19-007818-index.htm
2020-08-03Paula RaganPresident and CEOSell2,400.007.4517,880.00208,912.00https://www.sec.gov/Archives/edgar/data/1501697/000162828020011642/0001628280-20-011642-index.htm
2020-07-02Paula RaganPresident and CEOSell2,400.009.0521,720.00211,312.00https://www.sec.gov/Archives/edgar/data/1501697/000162828020010212/0001628280-20-010212-index.htm
2020-06-03Paula RaganPresident and CEOSell9,707.008.8886,198.16213,712.00https://www.sec.gov/Archives/edgar/data/1501697/000162828020008920/0001628280-20-008920-index.htm
2020-06-02Paula RaganPresident and CEOSell2,400.008.6520,760.00223,419.00https://www.sec.gov/Archives/edgar/data/1501697/000162828020008920/0001628280-20-008920-index.htm
2020-06-01Paula RaganPresident and CEOSell4,275.008.6336,893.25225,819.00https://www.sec.gov/Archives/edgar/data/1501697/000162828020008920/0001628280-20-008920-index.htm
2020-05-04Paula RaganPresident and CEOSell2,400.008.9221,408.00230,094.00https://www.sec.gov/Archives/edgar/data/1501697/000162828020006483/0001628280-20-006483-index.htm
2020-04-02Paula RaganPresident and CEOSell2,400.008.4020,160.00232,494.00https://www.sec.gov/Archives/edgar/data/1501697/000162828020004587/0001628280-20-004587-index.htm
2020-03-02Paula RaganPresident and CEOSell2,400.0010.6425,536.00234,894.00https://www.sec.gov/Archives/edgar/data/1501697/000162828020002798/0001628280-20-002798-index.htm
2019-06-17Paula RaganPresident and CEOBuy55,928.00237,294.00https://www.sec.gov/Archives/edgar/data/1501697/000089924319017419/0000899243-19-017419-index.htm
2020-08-14Adam S. MostafaChief Financial OfficerBuy16,250.0024,173.00https://www.sec.gov/Archives/edgar/data/1501697/000162828020012846/0001628280-20-012846-index.htm
2020-08-17Derek M MeisnerGeneral CounselBuy12,500.0025,000.00https://www.sec.gov/Archives/edgar/data/1501697/000162828020012840/0001628280-20-012840-index.htm
2020-08-14Paula RaganPresident and CEOBuy44,826.00253,738.00https://www.sec.gov/Archives/edgar/data/1501697/000162828020012842/0001628280-20-012842-index.htm
2020-10-05Paula RaganPresident and CEOSell1,797.007.0012,579.00284,923.00https://www.sec.gov/Archives/edgar/data/1501697/000162828020014331/0001628280-20-014331-index.htm
2020-10-02Paula RaganPresident and CEOSell603.007.004,221.00286,720.00https://www.sec.gov/Archives/edgar/data/1501697/000162828020014296/0001628280-20-014296-index.htm
2020-09-09Paula RaganPresident and CEOSell8,840.008.0471,073.60287,323.00https://www.sec.gov/Archives/edgar/data/1501697/000162828020013422/0001628280-20-013422-index.htm
2020-09-21Adam S. MostafaChief Financial OfficerSell10,834.007.0876,704.7229,589.00https://www.sec.gov/Archives/edgar/data/1501697/000162828020013832/0001628280-20-013832-index.htm
2020-09-02Paula RaganPresident and CEOSell2,400.007.9919,176.00296,163.00https://www.sec.gov/Archives/edgar/data/1501697/000162828020013295/0001628280-20-013295-index.htm
2020-08-17Paula RaganPresident and CEOBuy44,825.00298,563.00https://www.sec.gov/Archives/edgar/data/1501697/000162828020012842/0001628280-20-012842-index.htm
2020-08-14Renato SkerljChief Scientific OfficerBuy8,750.0039,160.00https://www.sec.gov/Archives/edgar/data/1501697/000162828020012844/0001628280-20-012844-index.htm
2020-08-17Adam S. MostafaChief Financial OfficerBuy16,250.0040,423.00https://www.sec.gov/Archives/edgar/data/1501697/000162828020012846/0001628280-20-012846-index.htm
2020-09-09Renato SkerljChief Scientific OfficerSell5,834.008.0546,963.7042,076.00https://www.sec.gov/Archives/edgar/data/1501697/000162828020013423/0001628280-20-013423-index.htm
2020-08-17Renato SkerljChief Scientific OfficerBuy8,750.0047,910.00https://www.sec.gov/Archives/edgar/data/1501697/000162828020012844/0001628280-20-012844-index.htm
2020-06-30Adam S. MostafaOfficerSell1,725.009.0415,594.008,839.00https://www.sec.gov/Archives/edgar/data/1501697/000162828020010103/0001628280-20-010103-index.htm